Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602635" target="_blank" >RIV/61989592:15110/20:73602635 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/20:00116254 RIV/00216208:11110/20:10416834 RIV/00064190:_____/20:N0000008 RIV/00209805:_____/20:00078442

Výsledek na webu

<a href="https://link.springer.com/article/10.1007%2Fs11523-020-00744-8" target="_blank" >https://link.springer.com/article/10.1007%2Fs11523-020-00744-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11523-020-00744-8" target="_blank" >10.1007/s11523-020-00744-8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib

Popis výsledku v původním jazyce

Background Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. Objective To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. Patients and Methods Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra.

Název v anglickém jazyce

Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib

Popis výsledku anglicky

Background Sarcopenia is common in advanced cancer and correlates with poor performance status, increased risk of treatment-related toxicity, and shortened survival. Inhibitors of the vascular endothelial growth factor pathway have been associated with development or deterioration of sarcopenia. Objective To assess the prevalence and impact of sarcopenia on survival in patients with metastatic renal cell carcinoma (mRCC) treated with cabozantinib, a novel, highly potent multikinase inhibitor. Patients and Methods Patients treated with cabozantinib for mRCC progressing on other targeted therapies with available computed tomography (CT) scans acquired at the time of initiation of cabozantinib and on the first restaging were evaluated retrospectively. Muscle mass was assessed based on striated muscle area at the level of the third lumbar vertebra.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Targeted Oncology

ISSN

1776-2596

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

FR - Francouzská republika

Počet stran výsledku

7

Strana od-do

673-679

Kód UT WoS článku

000555352100001

EID výsledku v databázi Scopus

2-s2.0-85089013138